We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Stem Cell Spray Technology Could Help Treat Severe Wounds

By HospiMedica International staff writers
Posted on 05 Oct 2016
Print article
Image: The SkinGun device is designed to spray a solution of a patient’s own stem cells onto a wound site for faster healing (Photo courtesy of RenovaCare).
Image: The SkinGun device is designed to spray a solution of a patient’s own stem cells onto a wound site for faster healing (Photo courtesy of RenovaCare).
A quick-healing spray system uses a patient’s own stem cells as an alternative to conventional skin graft surgery, which can be painful, prone to complications, and slow-to-heal.

The CellMist System is an innovative investigational treatment for processing and spraying a patient’s own stem cells onto wounds for rapid healing. The system is comprised of the CellMist Solution, a liquid suspension containing a patient’s own stem cells which are isolated from a small sample of their skin, using a patented extraction process. The second component of the system is the SkinGun device, which gently sprays the CellMist Solution on to a wound site for rapid healing. Once sprayed onto the wound site, the patient’s stem cells go to work, naturally and rapidly regenerating damaged skin.

Patented SkinGun technology results in 200-times more droplets formed than in conventional syringe deposition; for example, in an 8 cm diameter surface area, the SkinGun can deliver more than 20,000 evenly distributed droplets, versus only 91 droplets by conventional needle and syringe methods. The CellMist System is designed to replace traditional skin grafts, requiring only a postage stamp-sized sample of donor skin, which can be processed within 90 minutes of arriving in an emergency room. The CellMist System is under development by RenovaCare (New York, NY, USA).

“The prospect of spraying a patient’s own stem cells onto burns and wounds to create rapid, scar-free healing is a promising alternative to today’s painful and disfiguring skin grafting procedures,” said Thomas Bold, President and CEO of RenovaCare. “For patients, we are working towards natural, rapid healing where their new skin can look and function as well as it once did. For surgeons, it’s a relief to no longer have to remove vast sheets of healthy skin and surgically stitch it to wound sites.”

Most adult stem cells are lineage-restricted (multipotent) and are generally referred to by their tissue origin (mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, etc). They have been successfully used for many years to treat leukemia and related bone cancers through bone marrow transplants. Adult somatic stem cells can now be artificially grown and differentiated into specialized cell types with characteristics consistent with cells of various tissues.

Related Links:
RenovaCare


Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
4K-3D NIR/ICG Video Endoscope
TIPCAM 1 Rubina
New
Surgical Positioning Accessory
Lateral Support Curved Short (10-360)

Print article

Channels

Critical Care

view channel
Image: Mesenchymal stromal cells are delivered directly into the lungs using a bronchoscope (Photo courtesy of Stem Cell Res Ther. 2025. DOI: 10.1186/s13287-025-04289-3)

Novel Intrabronchial Method Delivers Cell Therapies in Critically Ill Patients on External Lung Support

Until now, administering cell therapies to patients on extracorporeal membrane oxygenation (ECMO)—a life-support system typically used for severe lung failure—has been nearly impossible.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.